In clinic, TBL1XR1-RARB-positive variant APL patients were all resistant to ATRA therapy, and the combined chemotherapy was more effective, but most of them experienced the refractory/relapsed disease. The gene discussed is RARB; the disease is acute promyelocytic leukemia.